aTyr Pharma, Inc. (ATYR) SEC Filings & Earnings Calls

Future development requires additional capital through equity/debt offerings, collaborations, or licensing arrangements, posing financing risk.

“Future development of efzofitimod in the Planned Phase 3 Study in pulmonary sarcoidosis will require the Company to obtain additional capital through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.” · word for word

Nasdaq delisting risk

“On December 4, 2025, we received a deficiency notice ... the bid price of our common stock had closed below $1.00 per share”

Phase 3 trial failure

“The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48.”

Capital need for new Phase 3 study

“To conduct the Planned Phase 3 Study, in addition to implementing the Restructuring Plan, we will need to obtain additional capital through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.” · word for word

Kyorin agreement termination

“On May 12, 2026, we received notice of termination of the Kyorin Agreement with Kyorin.” · word for word

Securities class action litigation

“On October 9, 2025 and October 22, 2025, two substantially similar putative securities class action complaints were filed.” · word for word

No product revenue

“We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years at a minimum.” · word for word

Workforce reduction of 60% signals severe financial distress; reliance on FDA feedback for Phase 3 creates binary risk.

“Workforce reduction of approximately 60%; future development of efzofitimod in the planned Phase 3 study will require the Company to obtain additional capital.”

Key management departures (CFO, GC) may disrupt operations.

“Jill Broadfoot, CFO, will step down; Nancy Denyes, GC, will step down.”

Loss of partner for Japan development; aTyr must now fund development alone or find new partner.

“Kyorin terminated without cause; no new partner announced.”

Potential financial impact from lost milestones and royalties; no termination fee disclosed.

“No financial terms of termination disclosed.”

Delisting risk if stock price does not recover above $1.00 for 10 consecutive days by Nov 30, 2026.

“Nasdaq deficiency notice and compliance deadline.”

Lead asset Phase 3 failure

“The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48.” · word for word

Collaboration termination

“On May 12, 2026, we received notice of termination of the Kyorin Agreement with Kyorin.” · word for word

Regulatory pathway uncertainty

“There is no established U.S. Food and Drug Administration (FDA) regulatory pathway for approval of a drug in pulmonary sarcoidosis.” · word for word

Securities class action litigation

“On October 9, 2025 and October 22, 2025, two substantially similar putative securities class action complaints were filed.” · word for word

Capital need for new Phase 3

“This planned Phase 3 study and any potential need for additional clinical studies for efzofitimod in pulmonary sarcoidosis, will require a significant amount of additional time and resources to support approval. In addition, it will require us to obtain additional capital through equity offerings or partnering to conduct such studies.” · word for word

Clinical trial execution risk for Phase 3 pulmonary sarcoidosis study

“Phase 3 trial is planned but not yet initiated; enrollment and results are uncertain.”

Cash burn rate may require future financing

“Cash position $68.3M with no revenue disclosed; R&D and G&A expenses total $11.4M per quarter.”

Phase 3 trial failure

“The study did not meet its primary endpoint of change from baseline in mean daily OCS dose at week 48.” · word for word

No product revenue

“To date, we have not derived any revenue from product sales.” · word for word

Significant dilution risk

“To approve an amendment to the Company's Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 340,000,000 shares.” · word for word

Phase 3 EFZO-FIT study missed primary endpoint, creating regulatory uncertainty for efzofitimod in pulmonary sarcoidosis.

“The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.” · word for word

FDA meeting outcome uncertain; potential for additional trials or rejection.

“Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward.”

Clinical Trial Failure

“In September 2025, we announced top-line results from the EFZO-FIT study, including that the study did not meet its primary endpoint.”

Capital Needs and Dilution

“We will need to raise additional capital or enter into strategic partnering relationships to fund our operations.”

Regulatory Uncertainty

“There is no established FDA regulatory pathway for approval of a drug in pulmonary sarcoidosis.”

Phase 3 trial failure for lead candidate efzofitimod; primary endpoint not met, casting doubt on commercial viability.

“The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48.” · word for word

Regulatory uncertainty: FDA meeting in Q1 2026 may not lead to a viable path forward, potentially requiring additional trials or abandonment.

“We plan to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026 to review the results of the study and determine the path forward for efzofitimod in pulmonary sarcoidosis.” · word for word

Cash burn rate: $22.1M R&D expenses per quarter with $92.9M cash; runway may be limited without additional financing or partnership.

“Research and development expenses were $22.1 million for the third quarter 2025... Cash, cash equivalents, restricted cash and available-for-sale investments as of September 30, 2025, were $92.9 million.”

Phase 3 trial failure

“The study did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (OCS) dose at week 48.” · word for word

Securities class action litigation

“On October 9, 2025 and October 22, 2025, two substantially similar putative securities class action complaints were filed in the U.S. District Court for the Southern District of California, naming aTyr Pharma, Inc. and our Chief Executive Officer, Sanjay Shukla.” · word for word

Dependence on future capital raises

“We will need to raise substantial additional capital to fund our operations.” · word for word